Áhrif lyfsins fampridíns á skerta göngugetu sjúklinga með MS (Multiple Sclerosis)

Publisher Copyright: © 2021 Laeknafelag Islands. All rights reserved. INTRODUCTION: Fampridine is a drug for people with Multiple Sclerosis (MS). It is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to enhance cond...

Full description

Bibliographic Details
Published in:Læknablaðið
Main Authors: Guðjónsdóttir, Björg, Hjaltason, Haukur, Andrésdóttir, Guðbjörg Þóra
Other Authors: Læknadeild, Lyflækninga- og bráðaþjónusta, Önnur svið, Landspítali
Format: Article in Journal/Newspaper
Language:Icelandic
Published: 2021
Subjects:
Lyf
MS sjúkdómur
Fampridine
Gait function
MS
Symptomatic treatment
Walking
Potassium Channel Blockers/adverse effects
Multiple Sclerosis/diagnosis
Gait
Humans
Retrospective Studies
4-Aminopyridine/adverse effects
Gönguþjálfun
Göngulag
Multiple Sclerosis
Pharmaceutical Preparations
Læknisfræði (allt)
Iceland
Online Access:https://hdl.handle.net/20.500.11815/3122
https://doi.org/10.17992/LBL.2021.04.630
Description
Summary:Publisher Copyright: © 2021 Laeknafelag Islands. All rights reserved. INTRODUCTION: Fampridine is a drug for people with Multiple Sclerosis (MS). It is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to enhance conduction in demyelinated axons, thereby leading to improved gait in patients with MS. The purpose of this study was to examine the effect of fampridine on gait function in people with MS in the end of a 2 weeks trial drug period and to observe how many patients continued drug therapy. MATERIAL AND METHODS: Data from 41 individuals with MS was collected retrospectively for this study. Measurements were administered by physiotherapists and the results from the Timed 25-Foot Walk (T25FW) and 12-item Multiple Sclerosis Walking Scale (MSWS-12) were obtained from medical records from The National University Hospital of Iceland. RESULTS: The results showed a significant difference in walking speed before and at the end of trial period (p<0.0001). The average improvement in walking speed was 22%. Results also demonstrated a significant difference in MSWS-12 scores before and at the end of treatment (p<0.0001). The average improvement in MSWS-12 was 11.4 points. Eighteen individuals (43.9%) continued treatment after the trial period. CONCLUSION: Fampridine can have a positive effect on impaired gait function in people with MS and can be an important adjunct to treatment. Peer reviewed

Similar Items